Precigen announced that its first‑and‑only FDA‑approved therapy for adult recurrent respiratory papillomatosis (RRP), Papzimeos (zopapogene imadenovec‑drba), is gaining rapid market traction. Patient‑hub enrollment has doubled since November 2025, now exceeding 200 registered patients, and the company reports that 96% of its target centers nationwide have been engaged by the sales team that went fully deployed in September 2025.
Coverage for Papzimeos now includes Medicare and Medicaid, and private health plans cover approximately 170 million U.S. lives. The rapid expansion of payer access has driven the enrollment surge, as physicians can now prescribe the drug with confidence that reimbursement is secured. The company’s field engagement strategy—leveraging a dedicated sales force and a robust patient‑hub platform—has enabled near‑complete penetration of high‑volume RRP centers, positioning the drug as the preferred first‑line treatment in most practices.
Precigen’s manufacturing and supply‑chain infrastructure is fully operational, with cold‑chain logistics and distribution networks in place to meet current demand. The company’s AdenoVerse platform allows for scalable production, and the existing capacity can accommodate the projected growth in patient volume without significant additional capital outlay. This operational readiness removes a key execution risk that could otherwise delay commercialization momentum.
Financially, Precigen has historically reported significant net losses—$24 million in Q3 2024 and $325 million in Q3 2025—largely driven by non‑cash items such as warrant liabilities and deemed dividends. The company’s cash‑flow breakeven target of the end of 2026 hinges on achieving sustained sales of Papzimeos. While the list price for a 12‑week course is $115,000 per vial (approximately $460,000 for the full course), analyst estimates for the cost per course range from $300,000 to $500,000. The article’s reference to a $400,000 annual net price reflects an extrapolation of the course price over a typical treatment cycle, but the precise pricing model remains a key variable in profitability projections.
Management emphasized the commercial momentum: Chief Commercial Officer Phil Tennant said, “Patient hub enrollment is doubling, payer coverage is expanding, and field engagement is near‑complete.” President and CEO Helen Sabzevari added, “The rapid adoption of Papzimeos, supported by strong safety and efficacy data, positions us to reach cash‑flow breakeven by the end of 2026.” Analysts note that the drug’s first‑in‑class status and the company’s robust supply chain give Precigen a competitive advantage, while the significant prior losses underscore the importance of scaling sales quickly to achieve profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.